Vanda Pharmaceuticals Inc. said that its profit fell 74 percent in the first quarter as it booked sharply lower royalty revenue and no product sales. The company earned $136,000, or broke even on a per-share basis.
Built on Novozymes’ Albufuse platform, the Albufuse Flex technology has been designed to enable users to adapt and control the pharmacokinetics of their target protein or peptide with retained efficacy, ensuring flexibility and optimal use.
Navitar Life Sciences, Inc., a leading optics manufacturer, announced they have entered into a binding agreement to acquire assets of Modulation Optics and their world?leading Hoffman Modulation Contrast Imaging Technology.
Aceto Corporation, a leader in the pharmaceutical, nutraceutical, and specialty chemical spaces, announced that Salvatore Guccione has been elected to the company's Board of Directors.
Thermo Fisher Scientific Inc. and TTP LabTech have combined the Thermo Scientific RapidStak microplate mover and the TTP LabTech mosquito X1 nanoliter pipettor to provide high-speed plate handling and precision, low-volume sampling from high-density formats.
Greiner Bio-One will be unveiling the CheckExtractor at EUROGIN 2011, a congress focusing on human papillomaviruses (HPV) and illnesses caused by HPV, such as cervical cancer.
Drugmaker Pfizer Inc. says the European commission has approved treating children with its medicine for a rare, deadly lung condition. The drug, Revatio, was approved in Europe about six years ago.
Rexahn Pharmaceuticals, Inc. announced that it has enrolled two-thirds of the total patients needed for its Phase 2b clinical trial to study the safety and efficacy of Serdaxin to treat major depressive disorder.
Elan Drug Technologies, the drug delivery unit of Elan Corporation, plc, announced that the first injectable product using EDT’s NanoCrystal technology has been approved by the European Commission.
The European Medicines Agency is working to monitor and evaluate the possible risk of radioactive contamination of medicines manufactured in Japan following the radiation leak from the Fukushima Daiichi nuclear power plant.
A study, “The Telomerase Activator TA-65 elongates short telomeres and increases healthspan of adult/old mice without increasing cancer incidence” describes TA-65’s mechanism of action and organismal response.
Provectus Pharmaceuticals, Inc. received orphan drug designation by the U.S. Food and Drug Administration (FDA) for Rose Bengal, the active ingredient in oncology drug PV-10, for the treatment of hepatocellular carcinoma (HCC)– the most common form of liver cancer.
Debiopharm Group and Aurigene Discovery Technologies signed an agreement concerning the development and commercialization of Debio 1142, a novel inhibitor of an undisclosed oncology pathway.
Cancer drug developer Celldex Therapeutics Inc. reported a larger first-quarter loss, saying its revenue and investment income decreased. Celldex lost $10.1 million, or 31 cents per share.